Douglas E. Paull, MD, MS and Paul N. Uhlig, MD, MPA
Risk managers can help patient-subjects and clinician-researchers make informed novel device implantation decisions in the absence of preclinical trial data.
AMA J Ethics. 2020;22(11):E911-918. doi:
10.1001/amajethics.2020.911.
Haley Moulton, Benjamin Moulton, JD, MPH, Tim Lahey, MD, MMSc, and Glyn Elwyn, MD, PhD, MSc
Shared decision making in research informed consent conversations is complex due to diverse and potentially divergent interests of investigators and patient-subjects.
AMA J Ethics. 2020;22(5):E365-371. doi:
10.1001/amajethics.2020.365.
William F. Parker, MD, MS and Marshall H. Chin, MD, MPH
Given organ scarcity, transplantation programs state that patient promises of compliance cannot be taken at face value, excluding candidates who are deemed untrustworthy.
AMA J Ethics. 2020;22(5):E408-415. doi:
10.1001/amajethics.2020.408.
Corporatization in health care has complicated clinicians’ and organizations’ efforts to balance interests of individual patients against an organization’s bottom line.
AMA J Ethics. 2020;22(3):E187-192. doi:
10.1001/amajethics.2020.187.